El-Khayat H, Yakoot M, El-Shabrawi M, et al. - Researchers evaluated the risk of reactivation of hepatitis B virus (HBV) infection in adolescent patients infected with chronic hepatitis B virus (HBV) and positive for HBsAg and HBcAbs. They included 115 adolescent patients from 12 to 17 years of age, infected with chronic HCV and positive for HBcAbs with or without HBsAg and provided them treatment with 1 tablet daily of the fixed-dose combination sofosbuvir/ledipasvir for 12 weeks. Results revealed no HBV reactivation in these treated adolescents. Although results are reassuring, close monitoring of liver functions is still recommended in order not to miss even rare cases of such a potentially serious condition.